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ABSTRACT: The inefficient delivery of proteins into mammalian cells remains a major barrier to realizing the therapeutic potential of many 
proteins. We and others have previously shown that superpositively charged proteins are efficiently endocytosed and can bring associated 
proteins and nucleic acids into cells. The vast majority of cargo delivered in this manner, however, remains in endosomes and does not reach 
the cytosol. In this study we designed and implemented a screen to discover peptides that enhance the endosomal escape of proteins fused to 
superpositively charged GFP (+36 GFP). From a screen of peptides previously reported to disrupt microbial membranes without known 
mammalian cell toxicity, we discovered a 13-residue peptide, aurein 1.2, that substantially increases cytosolic protein delivery by up to ~5-fold 
in a cytosolic fractionation assay in cultured cells. Four additional independent assays for non-endosomal protein delivery collectively suggest 
that aurein 1.2 enhances endosomal escape of associated endocytosed protein cargo. Structure-function studies clarified peptide sequence 
and protein conjugation requirements for endosomal escape activity. When applied to the in vivo delivery of +36 GFP–Cre recombinase fu-
sions into the inner ear of live mice, fusion with aurein 1.2 dramatically increased non-endosomal Cre recombinase delivery potency, resulting 
in up to 100% recombined inner hair cells and 96% recombined outer hair cells, compared to 0-4% recombined hair cells from +36-GFP-Cre 
without aurein 1.2. Collectively, these findings describe a genetically encodable, endosome escape-enhancing peptide that can substantially 
increase the cytoplasmic delivery of cationic proteins in vitro and in vivo.
INTRODUCTION 
Proteins that bind extracellular targets, including monoclonal 
antibodies1, Fc fusions2, and cytokines3, have served as important 
therapeutics4. Fully realizing the therapeutic potential of proteins, 
however, requires methods to enable exogenous proteins to access 
intracellular targets. Because the vast majority of proteins cannot 
spontaneously cross cell membranes, the development of intracel-
lular protein delivery methods could facilitate applications includ-
ing enzyme replacement therapies for metabolic diseases5, tran-
scription factor-driven changes in cell fate6, and genome editing7.  
Several methods for protein delivery have been explored in the 
past decade, including cell-penetrating peptides (CPPs)8, penta-arg 
proteins9, receptor ligands10, and lipid nanoparticles11. While these 
and other methods have advanced the field of protein delivery, 
challenges including cytotoxicity, lack of generality, low potency, or 
poor in vivo activity continue to limit their therapeutic rele-
vance12,13.  
We previously reported the discovery of superpositively-
charged proteins, a class of engineered and naturally occurring 
proteins that have abnormally high net positive charge, and their 
ability to potently deliver proteins and nucleic acids into mammali-
an cells14-17. While superpositive proteins are very efficiently endo-
cytosed18,19 and can be more effective for protein delivery than 
CPPs15, the vast majority of endocytosed proteins remain seques-
tered in endosomes18 that either mature into lysosomes, resulting in 
protein degradation, or are recycled to the surface of the cell20, 
resulting in extracellular protein release (Figure 1A). As a result, 
relatively high concentrations (µM) of exogenous protein are typi-
cally needed for modest cytosolic or nuclear delivery. Although 
superpositively charged proteins can slow endosomal maturation18, 
the inefficiency of endosomal escape enables only a small fraction 
of delivered protein to reach the cytosol21.  
To address this protein delivery bottleneck, we sought to dis-
cover peptides that facilitate endosomal escape when fused to en-
docytosed superpositively charged proteins such as +36 GFP. 
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Membrane-active peptides such as influenza-derived HA2 have 
been reported to be endosomolytic22. However, many of these 
peptides, including HA2, are cytotoxic at concentrations required 
for protein delivery23,24. Antimicrobial peptides (AMPs) are a class 
of membrane-active peptides that penetrate microbial membranes 
to provide defense against bacteria, fungi, and viruses, often with 
high selectivity25. Given that many AMPs exhibit minimal toxicity 
to mammalian cells26, we hypothesized that the altered endosomal 
environment or endosomal membrane curvature could induce 
some AMPs to be endosomolytic without exhibiting significant 
mammalian cell toxicity at useful concentrations. To test this hy-
pothesis, we performed a screen of AMPs for their ability to in-
crease protein delivery into the cytosol. 
 
Figure 1. (A) Overview of protein delivery in mammalian cells. Cati-
onic macromolecules such as +36 GFP interact with anionic sulfated 
proteoglycans on the cell surface and are endocytosed and sequestered 
in early endosomes. The early endosomes can acidify into late endo-
somes or lysosomes. Alternatively, early endosomes may be trafficked 
back to the cell surface as part of the membrane-recycling pathway. To 
access the cytoplasm, an exogenous cationic protein must escape endo-
somes before it is degraded or exported. (B) Sortase-mediated conju-
gation of peptides with +36 GFP–Cre recombinase prior to screening. 
Sortase was used to conjugate synthetic peptides containing a C-
terminal LPETGG with expressed +36 GFP–Cre containing an N-
terminal GGG. The resulting peptide–LPETGGG–+36 GFP–Cre 
fusion proteins have the same chemical composition as expressed re-
combinant proteins, but are more easily assembled. 
A major challenge to developing agents that enhance endoso-
mal escape is the lack of well-established assays that can distinguish 
proteins trapped in the endosomes from proteins released into the 
cytosol. Commonly used enzyme delivery assays involve substrates 
and products that can freely diffuse through membranes and can-
not differentiate between endosomal and cytosolic proteins. To 
overcome this challenge, we used multiple independent assays that 
reflect the interaction of a variety of cargo with a variety of cytosolic 
targets to evaluate endosomal escape of AMP–protein fusions.  
In this study, we discovered aurein 1.2 (GLFDIIKKIAESF) as a 
peptide that enhances the endosomal escape of a variety of cargo 
fused to +36 GFP. We elucidated structure-function relationships 
within aurein 1.2 using alanine scanning and mutational analysis. 
Results from three independent delivery assays confirmed that 
treatment of mammalian cells with cargo proteins fused to aurein 
1.2–+36 GFP result in more efficient cytosolic delivery than the 
same proteins fused to +36 GFP alone. Finally, we describe the 
ability of aurein 1.2 to enhance non-endosomal protein delivery in 
vivo. Cre recombinase enzyme was delivered into hair cells in the 
cochlea (inner ear) of live mice with much greater (> 20-fold) po-
tency when fused with aurein 1.2 than in the absence of the pep-
tide. These results together provide a simple molecular strategy for 
enhancing the cytosolic delivery of proteins in cell culture and in 
vivo that is genetically encoded, localized to cargo molecules, and 
does not require global treatment with cytotoxic small molecules. 
 
RESULTS 
Preparation of antimicrobial peptide conjugates of super-
charged GFP–Cre fusion proteins. We sought AMPs from the 
Antimicrobial Peptide Database27 that are ≤ 25 amino acids long 
(to facilitate their preparation and conjugation to +36 GFP), lack 
post-translational modifications, and are not known to be toxic to 
mammalian cells. Based on these criteria, we identified 36 AMPs 
ranging from 9 to 25 amino acids in length (Table 1). Each of the 
peptides was synthesized on solid phase with an LPETGG se-
quence appended to their C-terminus to enable sortase-catalyzed 
conjugation28 (Figure 1B). Assembly of proteins using sortase 
proved more amenable to rapid screening than the construction 
and expression of the corresponding fusions, especially since sever-
al AMP fusions do not express efficiently in E. coli. 
The peptides were conjugated to purified GGG–(+36 GFP)–
Cre using our previously described evolved sortase A enzyme 
(eSrtA)28. Sortase catalyzes the transpeptidation between a sub-
strate containing the C-terminal LPETGG and a substrate contain-
ing an N-terminal glycine to form a native peptide bond linkage 
and a protein identical to the product of translational fusion.  
Table 1. List of peptides chosen from the Antimicrobial Pep-
tide Database (APD) 
Label  APD number  Sequence  
 Conjugation  
efficiency  
A  AP00408  FLFPLITSFLSKVL  55%  
B  AP00405-11  FISAIASMLGKFL  70%  
C  AP00327  GWFDVVKHIASAV  -  
D  AP01434  FFGSVLKLIPKIL  -  
E  AP00013  GLFDIIKKIAESF  77%  
F  AP00025  HGVSGHGQHGVHG  20%  
G  AP00094  FLPLIGRVLSGIL  -  
(+) 
(+) (+) 
(+) 
Endocytosis 
Early 
endosomes 
Mature 
endosomes 
Endosomal 
escape 
Lysosomal 
degradation 
Decreasing pH 
(-) 
Membrane recycling 
(+) 
(+) 
GGG 
GGG-+36GFP-Cre 
Sortase Peptide stock solutions 
GGG LPETGG 
Sortase-mediated peptide 
conjugation 
Electrostatic 
interaction with 
proteoglycans 
A 
B 
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H  AP00012  GLFDIIKKIAESI  28%  
I  AP00014  GLLDIVKKVVGAFGSL  -  
J  AP00015  GLFDIVKKVVGALGSL  13%  
K  AP00016  GLFDIVKKVVGAIGSL  -  
L  AP00017  GLFDIVKKVVGTLAGL  18%  
M  AP00018  GLFDIVKKVVGAFGSL  -  
N  AP00019  GLFDIAKKVIGVIGSL  -  
O  AP00020  GLFDIVKKIAGHIAGSI  -  
P  AP00021  GLFDIVKKIAGHIASSI  -  
Q  AP00022  GLFDIVKKIAGHIVSSI  -  
R  AP00101  FVQWFSKFLGRIL  51%  
S  AP00351  GLFDVIKKVASVIGGL  11%  
T  AP00352  GLFDIIKKVASVVGGL  -  
U  AP00353  GLFDIIKKVASVIGGL  4%  
V  AP00567  VWPLGLVICKALKIC  4%  
W  AP00597  NFLGTLVNLAKKIL  34%  
X  AP00818  FLPLIGKILGTIL  14%  
Y  AP00866  FLPIIAKVLSGLL  86%  
Z  AP00870  FLPIVGKLLSGLL  -  
AA  AP00875  FLSSIGKILGNLL  88%  
AB  AP00898  FLSGIVGMLGKLF  70%  
AC  AP01211  TPFKLSLHL  81%  
AD  AP01249  GILDAIKAIAKAAG  20%  
AE  AP00013-G  LFDIIKKIAESF  63%  
AF  AP00013-2x  LFDIIKKIAESGFLFDIIKKIAESF  -  
AG  AP00722-75  GLLNGLALRLGKRALKKIIKRLCR  -  
AH  His13  GHHHHHHHHHHHHH  -  
AI  AP00512  FKCRRWQWRM  42%  
AJ  AP00553  KTCENLADTY  -  
Peptides were synthesized with a C-terminal LPETGG tag to enable 
conjugation with an evolved sortase (eSrtA). Conjugation efficiencies 
were calculated based on LC-MS results using peak abundance as de-
termined through MaxEnt protein deconvolution. 
The efficiency of eSrtA-mediated conjugation varied widely 
among the peptides (Supporting Information Figure S1). Of the 36 
peptides chosen for screening, 20 showed detectable (4% to 88%) 
sortase-mediated conjugation to +36 GFP–Cre, as observed by 
LC-MS, to generate desired peptide–LPETGGG–(+36 GFP)–Cre 
fusion proteins (Table 1). Unreacted peptide was removed by ul-
trafiltration with a 30-kD molecular weight cut off membrane.  
Primary screen for endosomal escape. We assayed the ability 
of each peptide–(+36 GFP)–Cre recombinase fusion when added 
to culture media to effect recombination in BSR.LNL.tdTomato 
cells15, a hamster kidney cell line derived from BHK-21 (Support-
ing Information Figure S2). Because Cre recombinase must enter 
the cell, escape endosomes, enter the nucleus, and catalyze recom-
bination to generate tdTomato fluorescence, this assay reflects the 
availability of active, non-endosomal recombinase enzyme that 
reaches the nucleus. As a positive control, we treated cells with +36 
GFP–Cre and chloroquine, a known endosome-disrupting small 
molecule 29.  
Figure 2. Primary screen for cytosolic delivery of Cre recombinase in 
BSR.LNL.tdTomato cells. Initial screen of 20 peptide–(+36 GFP)–
Cre conjugated proteins. Cytosolic Cre delivery results in recombina-
tion and tdTomato expression. The percentage of tdTomato positive 
cells was determined by fluorescence image analysis. 250 nM+36 
GFP–Cre was used as the no-peptide control (NP), and addition of 
100 µM chloroquine was used as the positive control (+). Cells were 
treated with 250 nM protein for 4 h in serum-free DMEM. Cells were 
washed and supplanted with full DMEM and incubated for 48 h. Error 
bars represent the standard deviation of three independent biological 
replicates. 
The reporter BSR.LNL.tdTomato cells were incubated with 
250 nM of each peptide–(+36 GFP)–Cre protein in serum-free 
media. In the absence of any conjugated peptide, treatment of re-
porter cells with 250 nM +36 GFP–Cre protein resulted in 4.5% of 
the cells expressing tdTomato, consistent with previous reports18. 
The same concentration of protein incubated with 100 µM chloro-
quine as a positive control resulted in an average of 48% recom-
bined cells (Figure 2). The results of chloroquine treatment varied 
substantially between independent replicates. As chloroquine is 
known to be toxic to cells above 100 µM, we speculate that this 
variability arises from the small differences between chloroquine's 
efficacious and toxic dosages. 
Ten of the screened peptide conjugates resulted in recombina-
tion efficiencies that were significantly above that of +36 GFP–Cre 
(Figure 2). The most potent functional delivery of Cre was ob-
served with aurein 1.2–+36 GFP–Cre (Table 1, entry E). Treat-
ment with aurein 1.2–+36 GFP–Cre resulted in an average of 40% 
recombined cells, comparable to that of the chloroquine positive 
control (Figure 2). To investigate the impact of differential conju-
gation efficiency on peptide performance, we compared citropin 
1.3 (Table 1, entry U), which displayed a moderate level of recom-
bination and the lowest level of conjugation (4%), to aurein 1.2, 
which has the highest level of recombination and also a high level of 
conjugation (77%). 
Both aurein 1.2–+36 GFP–Cre and citropin 1.3–+36 GFP–Cre 
were cloned, expressed, and purified as fusion proteins. The re-
combination signal from treatment with 250 nM of expressed au-
rein 1.2–+36 GFP–Cre was 10.4-fold above that of +36 GFP–Cre. 
In contrast, treatment with 250 nM expressed citropin 1.3–+36 
GFP–Cre did not induce any enhanced Cre delivery. When the 
treatment concentration was increased to 1 µM, aurein 1.2–+36 
GFP–Cre and citropin 1.3–+36 GFP–Cre resulted in 3.8-fold and 
3.0-fold higher recombination levels, respectively, than that of +36 
GFP–Cre alone (Figure 3A). These results suggest that while au-
rein 1.2 and citropin 1.3 both enhance the delivery of functional, 
non-endosomal +36 GFP–Cre protein at high concentrations, 
aurein 1.2 has greater efficacy than citropin 1.3 at lower concentra-
tions.  
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Figure 3. Efficacy and toxicity of recombinant expression fusions of 
aurein 1.2 ("E") and citropin 1.3 ("U"). (A) Cytosolic Cre delivery 
results in recombination and tdTomato expression. The percentage of 
tdTomato positive cells was determined by flow cytometry. Protein 
fusions were delivered at 125 nM, 250 nM, 500 nM, and 1 µM. (B) 
Toxicity of aurein 1.2 and citropin 1.3 as determined by CellTiterGlo 
(Promega) assay. Protein fusions were delivered at 125 nM, 250 nM, 
500 nM, and 1 µM. The labeled concentration of +36 GFP–Cre was 
used as the no peptide control (NP), and addition of 100 µM chloro-
quine was used as the positive control (+). Cells were treated with 250 
nM protein for 4 h in serum-free media. Cells were washed and sup-
planted with full DMEM and incubated for 48 h. Error bars represent 
the standard deviation of three independent biological replicates. 
Next, we evaluated the toxicity of each fusion protein at a range 
of concentrations (125 nM to 1 µM) using an ATP-dependent cell 
viability assay at 48 h after treatment. For +36 GFP–Cre, we ob-
served no cellular toxicity up to 1 µM treatment, which resulted in 
85% viable cells. Cells treated with 250 nM recombinant aurein 
1.2–+36 GFP–Cre and citropin 1.3–+36 GFP–Cre displayed 87% 
and 84% viability, respectively. Applying 1 µM treatments de-
creased cell viability to 70% and 66%, respectively (Figure 3B). In 
light of its activity and low cytotoxicity at 250 nM, we characterized 
in depth the ability of aurein 1.2 to enhance cytosolic protein deliv-
ery. 
Site-directed mutagenesis of aurein 1.2. Aurein 1.2 
(GLFDIIKKIAESF) is a potent AMP excreted from the Australian 
tree frog, Litoria aurea30. Interestingly, citropin 1.3 
(GLFDIIKKVASVIGGL) is a closely related peptide and is excret-
ed from a different Australian tree frog, Litoria citropa31. While the 
properties of aurein 1.2 have been investigated for its anti-bacterial 
and anti-tumorogenic abilities30, its ability to enhance endosomal 
escape or macromolecule delivery has not been previously report-
ed. The free peptide is thought to adopt an amphipathic alpha heli-
cal structure in solution, but the length of the helix is too short to 
span a lipid bilayer32. Therefore it has been theorized that aurein 
1.2 disrupts membranes through a "carpet mechanism” in which 
peptides bind to the membrane surface in a manner that allows 
hydrophobic residues to interact with lipid tails and hydrophilic 
residues to interact with polar lipid head groups33. Above a critical 
concentration, the peptides are thought to alter the curvature of the 
membrane enough to break apart the compartment.  
Table 2. Site-directed mutagenesis of aurein 1.2  
Label Sequence  
Aurein 1.2 GLFDIIKKIAESF  
G1A ALFDIIKKIAESF  
L2A GAFDIIKKIAESF  
F3A GLADIIKKIAESF  
D4A GLFAIIKKIAESF  
I5A GLFDAIKKIAESF  
I6A GLFDIAKKIAESF  
K7A GLFDIIAKIAESF  
K8A GLFDIIKAIAESF  
I9A GLFDIIKKAAESF  
E11A GLFDIIKKIAASF  
S12A GLFDIIKKIAEAF  
F13A GLFDIIKKIAESA  
K7H GLFDIIHKIAESF  
K8H GLFDIIKHIAESF  
E11H GLFDIIKKIAHSF  
K7R GLFDIIRKIAESF  
K8R GLFDIIKRIAESF  
E11R GLFDIIKKIARSF  
E11D GLFDIIKKIADSF  
An alanine scan was performed on aurein 1.2 to determine positions 
that tolerate mutation. Charged amino acids at tolerant positions were 
then replaced with histidines or other charged amino acids in an at-
tempt to increase endosomal escape efficiency. All constructs were 
expressed as recombinant fusion proteins with +36 GFP–Cre. 
To identify the residues involved in enhancing non-endosomal 
protein delivery, we performed an alanine scan of the 13 amino acid 
positions of aurein 1.2 by cloning, expressing, and purifying each 
alanine mutant of aurein 1.2–+36 GFP–Cre. The resulting fusion 
proteins were assayed in BSR.LNL.tdTomato reporter cells as de-
scribed above (Table 2). Seven positions were moderately to highly 
intolerant of alanine substitution. Six positions retained >70% of 
the activity of unmutated aurein 1.2–+36 GFP–Cre (Figure 4A). 
At each of these tolerant positions, which included three positions 
with charged residues (K7, K8, and E11 from Table 2), we generat-
ed additional mutations in an effort to improve activity. In total, 19 
mutants of aurein 1.2 were generated and tested using the Cre re-
combination assay. Two of the aurein variants, K8R and S12A, 
exhibited potentially improved overall recombination efficiency 
but also increased toxicity at 250 nM (Figure 4B). Given this in-
crease in toxicity, we decided to focus on the original peptide, au-
rein 1.2, and proceeded to characterize its potency through a series 
of complementary secondary assays.  
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Figure 4. Activity and cytotoxicity of aurein 1.2 variants fused to +36 
GFP–Cre(A) The percentage of tdTomato positive cells was deter-
mined by flow cytometry. (B) Toxicity as determined by CellTiterGlo 
(Promega) assay. For (b) and (c), 250 nM+36 GFP–Cre was used as 
the no peptide control (NP), and addition of 100 µM chloroquine was 
used as the positive control (+). Cells were treated with 250 nM pro-
tein for 4 h in serum-free DMEM. Cells were washed and supplanted 
with full DMEM and incubated for 48 h. 
Independent assays of endosomal escape. Although endo-
somal escape is widely considered to be the major bottleneck of 
cationic protein delivery34, few assays quantify the ability of pro-
teins to escape endosomes on a single-cell basis. To quantify cyto-
solic delivery of supercharged proteins in individual cells, we ap-
plied a glucocorticoid receptor (GR) translocationassay35 de-
scribed by Schepartz and colleagues9,36. In untreated HeLa cells 
expressing mCherry-labeled GR (GR-mCherry), the GR distrib-
utes nearly uniformly throughout the cell interior, resulting in a 
nuclear-to-cytoplasm translocation ratio (TR) of 1.17 (Figure 5A 
and 5B). Upon treatment with the cell-permeable glucocorticoid 
dexamethasone-21-thiopropionic acid (SDex) at a concentration of 
1 µM for 30 min, GR-mCherry relocates almost exclusively to the 
nucleus, resulting in a TR of 3.77 (Figure 5A and 5B). 
 
Figure 5. Investigating the ability of +36 GFP and aurein 1.2–+36 
GFP dexamethasone-conjugates to reach the cytosol and activate GR 
translocation. (A) Images of HeLa cells expressing GR-mCherry treat-
ed in the presence and absence of 1 µM dexamethasone (Dex)-protein 
conjugates for 30 min at 37 °C. (B) Nuclear-to-cytosol GR-mCherry 
fluorescence ratios (translocation ratios) of respective Dex-protein 
conjugates determined using CellProfiler®. (C) GR-mCherry translo-
cation ratios resulting from cells treated in the presence and absence of 
+36 GFPDex and endocytic inhibitors. (D) GR-mCherry translocation 
ratios resulting from cells treated in the presence and absence of aurein 
1.2–+36 GFPDex and endocytic inhibitors. Statistical significance is 
measured by P-value. ns= P > 0.05, * = P ≤ 0.05, ** = P ≤ 0.01, *** = P ≤ 
0.001. 
We generated dexamethasone conjugates of +36 GFP (+36 
GFPDex) and aurein 1.2–+36 GFP (aurein 1.2–+36 GFPDex) via 
sortase-mediated conjugation (Supporting Information Figure S4). 
Conjugated to these proteins, SDex is no longer cell permeable and 
cannot activate the GR for nuclear translocation unless the protein-
SDex conjugate can access the cytosol. Treatment of HeLa cells 
expressing GR-mCherry with 1 µM aurein 1.2–+36 GFPDex for 30 
min resulted in a TR of 2.62, which was significantly greater (p < 
0.05) than that of +36 GFPDex (TR = 2.23). As positive controls, we 
treated these cells with canonical cell permeable peptides (TatDex 
and Arg8Dex) and miniature proteins containing a penta-Arg motif 
that reach the cytosol intact, with efficiencies exceeding 50% (5.3Dex 
and ZF 5.3Dex)37. Aurein 1.2-+36 GFPDex (TR=2.62), activated sig-
nificantly greater levels of GR-mCherry translocation (p < 0.001) 
than TatDex (TR = 1.87) and Arg8Dex (TR = 1.63) and similar levels 
evoked by miniature proteins 5.3Dex (TR = 2.62) and ZF 5.3Dex (TR 
= 2.38) (Figure 5A and 5B). Taken together, these results suggest 
that aurein 1.2–+36 GFPDex exhibits an improved ability to access 
the cytoplasm over +36 GFPDex and canonical cell permeable pep-
tides. 
As an additional, independent assay of non-endosomal protein 
delivery, we tested the ability of aurein 1.2 to enhance the non-
endosomal delivery of an evolved biotin ligase (BirA) enzyme de-
veloped by Ting and coworkers38. BirA catalyzes the biotinylation 
of a 15-amino acid acceptor peptide (AP). We transfected a 
mCherry-AP fusion plasmid into HeLa cells. Biotinylation of 
mCherry can only occur in the presence of cytosolic BirA. To as-
sess the non-endosomal delivery of +36 GFP–BirA protein, 
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mCherry-AP biotinylation was quantified by Western blot using 
fluorophore-labeled streptavidin and normalized to the mCherry 
signal (Supporting Information Figure S5A). Treatment with 250 
nM aurein 1.2–+36 GFP–BirA resulted in a 50% increase in bioti-
nylation signal compared with 250 nM of +36 GFP–BirA alone 
(Supporting Information Figure S5B). We also observed a dose-
dependent increase in AP-biotinylation across treatment concen-
trations (250 nM, 500 nM, and 1 µM) for both aurein 1.2–(+36 
GFP)–BirA and unfused +36 GFP–BirA constructs. These results 
are consistent with the results of the GR translocation assay, and 
further suggest that aurein 1.2 enhances the endosomal escape of 
superpositively charged proteins.  
In order to directly quantify the increase in non-endosomal de-
livery resulting from aurein 1.2, we performed a cytosolic fractiona-
tion experiment to calculate the cytosolic concentrations of deliv-
ered protein. HeLa cells were treated with +36 GFP or aurein 1.2–
+36 GFP at 250 nM, 500 nM, and 1 µM. After 30 min of treatment, 
cells were washed, homogenized, and fractionated by ultracentrifu-
gation. The cytosolic concentration of delivered protein was calcu-
lated from the GFP fluorescence of the cytosolic fraction together 
with a standard curve relating fluorescence to known concentra-
tions of +36 GFP and aurein 1.2–+36 GFP added to cytosolic ex-
tract (Supporting Information Figures S6B and 6C). At 250 nM, 
treatment with aurein 1.2–+36 GFP resulted in ~5-fold more deliv-
ered cytosolic protein than treatment with +36 GFP alone (Sup-
porting Information Figure S6A). This difference decreased with 
increasing protein concentration, likely due to the influence of 
alternate uptake pathways or delivery bottlenecks at high protein 
concentrations. In contrast, the total amount of aurein 1.2–+36 
GFP versus +36 GFP uptaken by cells was similar, with aurein 1.2–
+36 GFP showing 1.3-fold higher total cellular uptake at 250 nM. 
These results directly demonstrate that aurein 1.2 increases the 
cytosolic concentration of cationic proteins that enter cells pre-
dominantly through endosomes,14,18 and are consistent with the 
above findings that aurein 1.2 has the greatest effect on enhancing 
non-endosomal delivery at ~250 nM (Figure 3A). 
Effect of endocytic inhibitors on +36 GFP and aurein 1.2–
+36 GFP delivery. We previously reported that endocytosis plays 
a key role in the cytosolic delivery of superpositively charged pro-
teins18. To probe the role of endocytosis in the delivery of super-
charged proteins with or without aurein 1.2, we treated cells ex-
pressing GR-mCherry with either +36 GFPDex or aurein 1.2–+36 
GFPDex in the presence of known endocytic inhibitors. The cortical 
actin remodeling inhibitor N-ethyl-isopropyl amiloride (EIPA), the 
cholesterol-sequestering agent methyl-β-cyclodextrin (MBCD), 
and the endosomal vesicular ATPase inhibitor bafilomycin (Baf) all 
strongly reduced the ability of both proteins to stimulate GR-
mCherry translocation. Blocking maturation of Rab5+ vesicles by 
treatment with the phosphatidylinositol 3-kinase inhibitor wort-
mannin (Wort) did not influence reporter translocation of either 
+36 GFPDex or aurein 1.2–+36 GFPDex (Figure 5C and 5D). In con-
trast, treatment with the small-molecule dynamin II inhibitor 
Dynasore (Dyna) significantly suppressed the ability of +36 GFPDex 
to stimulate GR-mCherry translocation (TR = 1.64) (Figure 5C) 
but had little influence on the cytosolic delivery of aurein 1.2-+36 
GFPDex (TR = 2.30) (Figure 5D). Taken together, these results 
suggest that active endocytosis is required for uptake of +36 GFP 
and aurein 1.2–+36GFP into the cell interior, and that the two 
proteins may traffic differently into the cell interior. 
Aurein 1.2 can greatly increase protein delivery efficiency 
in vivo. To evaluate the ability of aurein 1.2 to increase the efficacy 
of cationic protein delivery in vivo, we delivered proteins to the 
inner ear of Cre reporter transgenic mice that express tdTomato 
upon Cre-mediated recombination. This animal model was chosen 
due to its confined injection volume, the presence of well-
characterized cell types, and the existence of genetic deafness mod-
els that would facilitate future studies of protein delivery to treat 
hearing loss. We previously showed that +36 GFP–Cre alone can 
be delivered to mouse retina,15 albeit resulting in only modest levels 
of recombination consistent with inefficient endosomal escape.  
Anesthetized postnatal day 2 (P2) mice were injected with 0.4 
µL of 50 µM +36 GFP–Cre or aurein 1.2–+36 GFP–Cre solutions 
in the scala media to access the cochlear cells. Five days after injec-
tion, the cochleas were harvested for immunolabeling of inner ear 
cell markers and imaging for tdTomato florescence (Figure 6A). 
We evaluated both the hair cells (Myo7a+) and supporting cells 
(Myo7a-) for td Tomato signal. The total number of hair cells and 
supporting cells (by DAPI labeling) in the sensory epithelium (SE) 
was used to determine the relative toxicity of aurein 1.2–+36 GFP–
Cre to the baseline treatment of +36 GFP–Cre (Figure 6A). Over-
all, an average of 96%, 92% and 66% of cochlear cells survived au-
rein 1.2–+36 GFP–Cre treatment as compared to +36 GFP–Cre 
treatment in the apex, middle, and base tissue samples, respectively 
(Figure 6A). +36 GFP–Cre treatment resulted in low levels of re-
combination only in inner hair cells (IHC) of the apex of the coch-
lea (4.4%) but not in the middle or base of the cochlear hair cells or 
any cochlear supporting cells. In contrast, treatment with aurein 
1.2–+36 GFP–Cre resulted in very high Cre-mediated recombina-
tion levels throughout the apex, middle, and base samples of outer 
hair cells (OHC) (96%, 91%, and 69%, respectively), inner hair 
cells (100%, 94%, and 70%, respectively), as well as supporting cells 
(arrows) (Figure 6A and 6C).  
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Figure 6. In vivo protein delivery of Cre recombinase into mouse neo-
natal cochleas. 0.4 µL of 50 µM +36 GFP–Cre or aurein 1.2–+36 GFP–
Cre were injected into the scala media. (A) Five days after injection, 
cochlea were harvested. Inner hair cells (IHC), outer hair cells (OHC) 
and supporting cells in the sensory epithelium (SE) were imaged for 
the presence of tdTomato, which is only expressed following Cre-
mediated recombination. Hair cells were labeled with antibodies 
against the hair-cell marker Myo7a. Gray/white = Myo7a, Red = 
tdTomato, Blue = DAPI. (B) To evaluate cytotoxicity, the number of 
outer hair cells and inner hair cells were measured by counting DAPI-
stained cells  (C) The percentage of tdTomato positive cells, reflecting 
successful delivery of functional Cre recombinase, was determined by 
fluorescence imaging.  
The observed levels of recombination in the inner hair cells 
from aurein 1.2–+36 GFP–Cre are comparable to that of adeno-
associated virus type 1 (AAV1) gene transfection39. For outer hair 
cells, we have previously shown similar levels of recombination 
using liposome-mediated delivery of supernegatively-charged 
GFP–Cre40. The aurein 1.2–+36 GFP–Cre delivery system is the 
only method that showed significant recombination levels in both 
inner and outer hair cells39,41, and does not require any virus or 
other molecules beyond a single polypeptide. Significantly, aurein 
1.2–+36 GFP–Cre also extended delivered recombinase activity to 
additional cochlear supporting cells. These results suggest aurein 
1.2-+36 GFP-Cre delivery system to be a promising method for in 
vivo protein delivery into both hair cells and supporting cells of the 
inner ear42.  
 
CONCLUSION 
We discovered a 13-residue peptide, aurein 1.2, that can in-
crease the efficiency of non-endosomal protein delivery by screen-
ing a panel of known membrane-active peptides. The results from a 
small screen of 22 peptides are consistent with our hypothesis that 
some peptides can selectively disrupt the endosomal membrane 
without disrupting the mammalian cell membrane. The effective-
ness of aurein 1.2 is highly dependent on its sequence, as several 
other closely related peptides did not enhance protein delivery 
(Tables 1 and 2). Subtle differences in amino acid composition led 
to dramatic changes in membrane activity among peptides tested, 
highlighting the difficulty of rationally designing peptides that en-
hance non-endosomal delivery. Moreover, the lack of correspond-
ence between peptide cationic charge and non-endosomal delivery 
efficiency suggests that aurein 1.2 does not enhance non-
endosomal delivery simply by promoting endocytosis.  While none 
of the tested variants of aurein 1.2 substantially outperformed the 
original peptide, we identified several amino acids that could be 
altered without loss of activity. These findings also provide a start-
ing point for further optimization to discover next-generation en-
dosomolytic peptides with improved efficacy and reduced toxicity.  
Four independent assays for non-endosomal protein delivery 
(Cre recombination, GR translocation, BirA activity on a cyto-
plasmic peptide, and cytosolic fractionation), together with the 
peptide mutational studies described above, collectively suggest 
that aurein 1.2-fusion enhances endosomal escape of superpositive-
ly charged proteins. Moreover, these assays collectively demon-
strated the ability of aurein 1.2 to mediate the non-endosomal de-
livery of +36 GFP fused to different proteins (or small molecules), 
suggesting that aurein 1.2 facilities endosomal escape in a manner 
that is at least somewhat cargo-independent.  
The in vivo protein delivery experiments described above re-
vealed dramatic increases in non-endosomal functional Cre re-
combinase delivery into the diverse inner ear cell types including 
hair cells and supporting cells of live mice upon fusion with aurein 
1.2. Indeed, aurein 1.2-fused +36 GFP–Cre construct resulted in 
highly efficient recombination levels across the main cochlear sen-
sory epithelial cell classes studied in this work, all but one of which 
were unaffected by +36 GFP–Cre treatment. Taken together, these 
results suggest that aurein 1.2 is a 13-residue, potent, genetically 
encodable, endosome escape-enhancing peptide that can greatly 
increase the efficiency of non-endosomal cationic protein delivery 
in vitro and in vivo without requiring the use of additional compo-
nents beyond the protein of interest.  
 
EXPERIMENTAL SECTION 
Construction of expression plasmids. Sequences of all con-
structs used in this paper are listed in the Supporting Information. 
All protein constructs were generated from previously reported 
plasmids for protein of interest cloned into a pET29a expression 
plasmid43. All plasmid constructs generated in this work will be 
deposited with Addgene.  
Expression and purification of proteins. E. coli BL21 STAR 
(DE3) competent cells (Life Technologies) were transformed with 
pET29a expression plasmids. Colonies from the resulting expres-
sion strain was directly inoculated in 1 L of Luria-Bertani (LB) 
broth containing 100 μg/mL of ampicillin at 37 °C to OD600 = ~1.0. 
Isopropyl β-D-1- thiogalactopyranoside (IPTG) was added at 0.5 
mM to induce expression and the culture was moved to 20 °C. 
After ~16 h, the cells were collected by centrifugation at 6,000 g 
and resuspended in lysis buffer (Phosphate buffered saline (PBS) 
with 1 M NaCl). The cells were lysed by sonication (1 sec pulse-on, 
1 sec pulse-off for 6 min, twice, at 6 W output) and the soluble 
lysate was obtained by centrifugation at 10,000 g for 30 min.  
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The cell lysate was incubated with His-Pur nickel-nitriloacetic 
acid (Ni-NTA) resin (Thermo Scientific) at 4 °C for 45 min to 
capture His-tagged protein. The resin was transferred to a 20-mL 
column and washed with 20 column volumes of lysis buffer plus 50 
mM imidazole. Protein was eluted in lysis buffer with 500 mM 
imidazole, and concentrated by Amicon ultra centrifugal filter (Mil-
lipore, 30-kDa molecular weight cut-off) to ~50 mg/mL. The elu-
ent was injected into a 1 mL HiTrap SP HP column (GE 
Healthcare) after dilution into PBS (5-fold). Protein was eluted 
with PBS containing a linear NaCl gradient from 0.1 M to 1 M over 
five column volumes. The eluted fractions containing protein were 
concentrated to 50 µM as quantified by absorbance at 488 nm as-
suming an extinction coefficient of 8.33 x 104 M-1cm-1 as previously 
determined 14, snap-frozen in liquid nitrogen, and stored in aliquots 
at -80 °C.  
Cell Culture. All cells were cultured in Dulbecco's modifica-
tion of Eagle's medium (DMEM w/glutamine, Gibco) with 10% 
fetal bovine serum (FBS, Gibco), 5 I.U. penicillin, and 5 g/mL 
streptamycin. All cells were cultured at 37 °C with 5% CO2. 
Peptide synthesis. Peptides were ordered from ChinaPeptides 
Co., LTD, each 4 mg, purity > 90%. HPLC and MALDI data were 
provided with lyophilized peptides. Peptides were resuspeneded in 
DMSO to a final concentration of 10 mM. 
Sortase conjugation. All reactions were performed in 100mM 
Tris buffer (pH 7.5) with 5mM CaCl2 and 1M NaCl. For peptide 
conjugation to the N-terminus of GGG–+36–GFP , 20 µM of pro-
tein with N-terminal Gly-Gly-Gly was incubated with 400 µM of 
peptide with C-terminal LPETGG and 1 µM eSrtA for 2 h at room 
temperature in a 50 µL reaction. The unreacted peptides were re-
moved through spin filtration with an Amicon Ultra-0.5 Centrifu-
gal Filter Unit (Millipore, 30-kDa molecular weight cut-off). The 
reaction mixture was washed twice with 500 µL of buffer each time 
to a final concentration of 50 µL. Conjugation efficiency was de-
termined through LC-MS (Agilent 6220 ESI-TOF) using protein 
deconvolution through MaxEnt (Waters) by comparing relative 
peak intensities. 
For conjugation of GGGKDex to +36–GFP–LPETG–His6, 10 
µM of protein was incubated with 400 µM of peptide and 2 µM 
eSrtA at room temperature. The reaction was quenched with 10 
mM ethylenediaminetetraacetic acid (EDTA) after 2 h. For aurein 
1.2–+36–GFP–LPETG–His6, a N-terminal His6–ENLYFQ was 
added to prevent sortase reaction with the N-terminal glycine of 
aurein 1.2. The N-terminal tag was removed with 200µM TEV 
protease at 4 °C for 16 h to release the native N-terminal sequence 
of aurein 1.2–+36–GFP. Successful conjugation of GGGKDex re-
moves the C-terminal His6 tag and allows for purification through 
reverse Ni-NTA column. Unreacted protein binds to the Ni-NTA, 
and the unbound protein was collected and concentrated as de-
scribed above. 
Plasmid transfection. Plasmid DNA was transfected using 
Lipofectamine 2000 (Life Technologies) according the manufac-
turer’s protocol.  
Synthesis of Dexamethasone-21 Thiopropionic Acid 
(SDex).  Synthesis of dexamethasone-21-mesylate was performed 
as previously described.44,45 2 g of dexamethasone stirring in 38 mL 
anhydrous pyridine under nitrogen was reacted with 467.2 m 
gmethanesulfonyl chloride (1.2 eq.) on ice for 1h, after which an-
other 311 methanesulfonmethanesulfonyl chloride was added and 
allowed to react overnight (16h) on ice.  Next, the reaction was 
added to 800 mL of ice water and Dexamethasone-21-Mesylate 
(Dex-21-OMs) formed a white precipitate.  The slurry was filtered 
and the precipitate washed with 800 mL of ice water, dried under 
high vacuum overnight and quantified by LC-MS (m/z 471.19 Da, 
83% yield). 
Dexamethasone-21-thiopopionic acid (SDex) was prepared as 
previously described.46 2.05 g of Dex-21-OMs was added to 2 eq. 
thiopropionic acid and 4 eq. triethylamine stirring in anhydrous 
acetone at room temperature overnight.  The following morning, 
the reaction was added to 800 mL of ice water and acidified with 1 
N HCl until SDex, visible as an off-white solid, precipitation was 
complete.  The mixture was filtered, washed with 800 mL ice cold 
water acidified to pH 1 with HCl, dried under high vacuum over-
night and analyzed by LC-MS (m/z 481.21 Da, 63% yield) (Sup-
porting Figure 7). 
Synthesis and Purification of GGGKDex. GGGKDex was syn-
thesized on Fmoc-Lys (Mtt)-Wang resin (BACHEM, D-2565) 
using microwave acceleratin (MARS, CEM). Coupling reactions 
were performed using 5 equivalents of Fmoc-Gly-OH (Novabio-
chem, 29022-11-5), 5 equivalents of PyClock (Novabiochem, 
893413-42-8) and 10 equivalents of diisopropylethylamine 
(DIEA) in N-methylpyrrolidone (NMP). Fmoc groups were re-
moved using 25% piperidine in NMP (efficiency quantified; 
ε299=6234 M-1cm-1 in acetonitrile) and Mtt groups were removed by 
incubating the Fmoc-GGGK(Mtt)-resin with 2% trifluoroacetic 
acid (TFA) in dichloromethane (DCM) for 20 min, after which the 
resin was washed with 2% TFA in DCM until the characteristic 
yellow color emitting from the Mttcation subsided. After Mtt re-
moval, SDex-COOH (Dex-21-thiopropinonic acid35) was coupled 
to the Nε of the lysine side-chain by incubating the Fmoc-GGGK-
resin with 2.5 eq. SDex-COOH, 2.5 eq. HATU, 2.5 eq. HOAt, 5 eq. 
DIEA and 5 eq. 2,6-lutidine in 2.5 mL NMP overnight, at room 
temperature, on an orbital shaker. After SDex-labeling, Fmoc-
GGGKDex-resin was washed thoroughly with NMP and DCM, the 
N-terminal Fmoc was removed using 25% piperidine in NMP, and 
crude peptides were dissociated from the resin by incubating the 
GGGKDex-resin in a cleavage cocktail composed of 81.5% trifluoro-
acetic acid (TFA), 5% thioanisole, 5% phenol, 5% water, 2.5% 
ethanedithiol and 1% triisopropylsilane for 30 min at 38 °C. Crude 
peptides were precipitated in 40 mL cold diethyl ether, resuspend-
ed in water, lyophilized and purified via reverse phase high-pressure 
liquid chromatography (HPLC) using a linear gradient of acetoni-
trile and water with 0.1% TFA across a C18 (VYDAC, 250mm x 10 
mm ID) column. Purified peptides were lyophilized and stored at 
4 °C. Polypeptide identity was confirmed by mass spectrometry on 
a Waters QToF LC-MS, and purity was measured by analytical 
reverse-phase HPLC (Shimadzu Instruments) using a C18 column 
(Poroshell 120 SB-C18, 2.7 µm, 100 mm x 3 mm ID, Agilent). 
Image processing for primary screen. BSR.LNL.tdTomato 
cells were plated at 10,000 cells per well in black 384-well plates 
(Aurora Biotechnologies). Cells were treated with Cre fusion pro-
teins diluted in serum-free DMEM 24 h after plating and incubated 
for 4 h at 37 °C. Following incubation, the cells were washed three 
times with PBS + 20 U/mL heparin. The cells were incubated a 
further 48 h in serum-containing media. Cells were fixed in 3% 
paraformaldehyde and stained with Hoescht 33342 nuclear dye. 
Images were acquired on an ImageXpress Micro automated micro-
scope (Molecular Devices) using a 4× objective (binning 2, gain 2), 
with laser- and image-based focusing (offset −130 µm, range ±50 
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µm, step 25 µm). Images were exposed for 10 ms in the DAPI 
channel (Hoechst) and 500 ms in the dsRed channel (tdTomato). 
Image analysis was performed using the cell-scoring module of 
MetaXpress software (Molecular Devices). All nuclei were detect-
ed with a minimum width of 1 pixel, maximum width of 3 pixels, 
and an intensity of 200 gray levels above background. Positive cells 
were evaluated for uniform signal in the dsRed channel (minimum 
width of 5 pixels, maximum width of 30 pixels, intensity > 200 gray 
levels above background, 10 µm minimum stained area). In total, 
nine images were captured and analyzed per well, and 16 wells were 
treated with the same fusion protein. The primary screen was com-
pleted in biological triplicate. 
Cre delivery assay. Uptake and delivery assays for Cre fusion 
proteins were performed as previously described 15. Briefly, proteins 
were diluted in serum-free DMEM and incubated on the cells in 
48-well plates for 4 h at 37 °C. Following incubation, the cells were 
washed three times with PBS + 20 U/mL heparin. The cells were 
incubated a further 48 h in serum-containing media prior to tryp-
sinization and analysis by flow cytometry. All flow cytometry were 
carried out on a BD Fortessa flow cytometer (Becton-Dickinson) 
using 530/30 nm and 610/20 nm filter sets. Toxicity for aurein 1.2 
and citropin 1.3 validation assays was determined using CellTiter-
Glo assay (Promega) in 96-well plates following manufacturer 
protocol. Toxicity for alanine scan mutational analysis was deter-
mined with LIVE/DEAD fixable far-red dead cell stain (Life Tech-
nologies) with 635 nm laser and 670/30 nm filter. 
GR-mCherry translocation assay. One day prior to transfec-
tion 10,000 HeLa cells in 200 µL of DMEM (10% FBS, 1x Pen-
Strep) were plated into single wells of a 96-well MatriCal glass 
bottom microplate (MGB096-1-2-LG-L) and allowed to adhere 
overnight. The following day, cells were transfected with GR-
mCherry9 using Lipofectamine® 2000 technologies. Following 
transfection, cells were allowed to recover overnight in DMEM (+ 
10% FBS). The following day, cells were treated with dexame-
thasone (Dex) or 1 µM Dex-protein conjugate in the presence or 
absence of inhibitor diluted into DMEM (without phenol red, 
+300 nM Hoescht33342). After 30 min, cells were washed twice 
with 200 µL of HEPES−Krebs−Ringer’s (HKR) buffer (140 mM 
NaCl, 2 mM KCl, 1 mM CaCl2, 1 mM MgCl2, and 10 mM HEPES 
at pH 7.4), after which 100 µL of HKR buffer was overlaid onto the 
cells and images were acquired on a Zeiss Axiovert 200M epifluo-
rescence microscope outfitted with Ziess AxiocammRM camera 
and an EXFO-Excite series 120 Hg arc lamp. The translocation 
ratio (the ratio of median GFP intensity in the nuclear and sur-
rounding regions) for individual cells was measured using CellPro-
filer® as described36. To examine the effect of endocytosis inhibi-
tors, HeLa cells were pretreated for 30 min with DMEM (without 
phenol red) containing inhibitors (80 µM Dynasore, 5 mM 
MBCD, 50 µM EIPA, 200 nM bafilomycin or 200 nM wortman-
nin) at 37 °C for 30 min before incubation with Dex or Dex-protein 
conjugates.  
BirA translocation assay. One day prior to transfection, 
100,000 HeLa cells in 1 mL of DMEM (10% FBS, 1x PenStrep) 
were plated into single wells of a 12-well tissue culture plate and 
allowed to adhere overnight. Cells were transfected with mCherry-
AP fusion protein using Lipofectamine® 2000 technologies accord-
ing to manufacture guidelines24 h before protein treatment. Next 
day, transfected cells were treated for 1 h at 37 °C with +36 GFP–
BirA or aurein 1.2–+36 GFP–BirA diluted in serum-free DMEM at 
250 nM, 500 nM and 1 µM concentrations. 250 nM +36 GFP–BirA 
+ 100 µM chloroquine was also used as a positive control for endo-
somal escape. The cells were washed three times with PBS contain-
ing heparin to remove excess supercharged proteins that were not 
internalized. The cells were then treated with 100 µL of 10 µM 
biotin and 1 mM ATP in PBS for 10 min. The reaction was 
quenched with excess (10 µL of 8 mM) synthesized AP before cells 
were trypsinized and lysed. To verify that extracellular BirA was not 
generating signal during lysis, 1 µM +36 GFP–BirA or aurein 1.2–
+36 GFP–BirA was added during the quench step to untreated 
wells. Cells were lysed with 100 µL of trypsin and lysed with QI-
Ashredder columns (Qiagen). 30 µL of lysate was loaded onto 4-
12% Bis-Tris Bolt gels in Bolt-MES buffer (Life Technologies) and 
ran for 20 min at 200 volts. Gels were transferred to PVDF mem-
brane using iBlot2 transfer system (Life Technologies). Biotinyla-
tion was measured through western blotting using the LI-COR 
quantitative infrared fluorescent antibodies and the Odyssey Im-
ager detection system. To normalize for transfection and gel load-
ing variables, the ratio of biotin signal to mCherry signal was used 
for comparison.  
Cytosolic fractionation assay. One day prior to fractionation, 
4x106 HeLa cells were plated in 20 mL of DMEM (10% FBS, 1x 
PenStrep, no phenol red) in 175-cm2 culture flasks and allowed to 
adhere for 15 hours. The following day, the media was removed 
from each flask and the cells were washed twice with clear DMEM 
(no FBS, no PenStrep, no phenol red). The media was replaced 
with 7 mL of clear DMEM containing +36 GFP or aurein 1.2–+36 
GFP at a concentration of 250 nM, 500 nM, or 1 μM. Several flasks 
were treated with clear DMEM to be used as negative controls and 
to generate calibration curves with the cytosolic extracts. The cells 
were incubated for 30 min at 37 °C, 5% CO2 after which they were 
washed three times with PBS. Using a cell-scraper, the cells were 
suspended in 5 mL of PBS, transferred into a 15 mL Falcon tube, 
and pelleted at 500 g for 3 min. The cells were resuspended in 1 mL 
PBS, counted using an automated cell counter (Auto T4, Cellome-
ter®), and pelleted again at 500 g for 3 min. The cell pellet was re-
suspended in ice-cold isotonic sucrose (290 mM sucrose, 10 mM 
imidazole, pH 7.0 with 1 mM DTT, and cOmplete™, EDTA-free 
protease inhibitor cocktail) and transferred to a glass test tube on 
ice. The cells were homogenized with an Omni TH homogenizer 
outfitted with a stainless steel 5 mm probe for three 30 s pulses on 
ice with 30 s pauses between the pulses. The homogenized cell 
lysate was sedimented at 350 Kg in an ultracentrifuge (TL-100; 
Beckman Coulter) for 30 min at 4 °C using a TLA 120.2 rotor. The 
supernatant (cytosolic fraction) was analyzed in a 96-well plate on 
a fluorescence plate reader (Synergy 2, BioTek, excitation = 485 
+/- 10 nm, emission = 528 +/- 10 nm). The concentration of the 
protein conjugate in the cytosol was determined using a standard 
curve relating fluorescence to known protein concentrations. To 
generate the standard curve, known concentrations of +36 GFP 
and aurein 1.2–+36 GFP between 0.2 nM and 1 μM were added to 
cytosolic extracts of the untreated negative controls. For back-
ground subtraction, several wells containing cytosolic extracts from 
untreated cells were averaged, and this average was subtracted from 
each well. 
Total protein delivery assay. One day prior to the experi-
ment, 100,000 HeLa cells/well were plated in DMEM (10% FBS, 
1x PenStrep, no phenol red) in 6-well plates and allowed to adhere 
for 15 hours. The following day, the media was removed from each 
well and the cells were washed twice with clear DMEM (no FBS, 
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no PenStrep, no phenol red). The media was replaced with 1 mL of 
clear DMEM containing +36 GFP or aurein 1.2–+36 GFP at con-
centrations of 250 nM, 500 nM, or 1 μM. The cells were incubated 
for 30 min at 37 °C, 5% CO2 after which they were washed three 
times with PBS containing 20 U/mL heparin (Sigma) to remove 
surface-bound cationic protein. The cells were trypsinized for 5 
min, pelleted in serum-containing DMEM for 3 min at 500 g, 
washed with 1 mL PBS, and pelleted again for 3 min at 500 g. The 
cell pellet was resuspended in 100 μL PBS. Flow cytometry was 
performed on a BD Accuri C6 Flow Cytometer at 25 °C. Cells were 
analyzed in PBS (excitation laser = 488 nm, emission filter = 533 
+/- 30 nm). At least 10,000 cells were analyzed for each sample. 
For background subtraction, wells were treated with clear DMEM 
only. The average of three untreated wells was subtracted from 
each +36 GFP conjugate-containing well. 
Microinjection of proteins to mouse inner ear. P1-2 
Gt(ROSA)26Sortm14(CAG-tdTomato)Hze mice were used for aurein 1.2–
+36–GFP–Cre and +36–GFP–Cre injection. The Rosa26-
tdTomato mice were from the Jackson Laboratory. Animals were 
used under protocols approved by the Massachusetts Eye &Ear 
Infirmary IACUC committee. Mice were anesthetized by hypo-
thermia on ice. Cochleostomies were performed by making an 
incision behind the ear to expose the cochlea. Glass micropipettes 
held by a micromanipulator were used to deliver the complex into 
the scala media, which allows access to inner ear hair cells. The 
total delivery volume for every injection was 0.4 µL per cochlea and 
the release was controlled by a micromanipulator at the speed of 69 
nL/min.  
Immunohistochemistry and quantification. 5 days after in-
jection, the mice were sacrificed and cochlea were harvested by 
standard protocols47. For immunohistochemistry, antibodies 
against hair-cell markers (Myo7a) and supporting cells (Sox2) 
were used following a previously described protocol47. To quantify 
the number of tdTomato positive cells after aurein 1.2–+36–GFP–
Cre and +36–GFP–Cre, we counted the total number of inner and 
outer hair cells in a region spanning 100 µm in the apex, middle, 
and base turn of the cochlea. 
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